OTCMKTS:SDMHF Sartorius Stedim Biotech (SDMHF) Stock Price, News & Analysis → Grab Your Free Bitcoin Today! (From Crypto Swap Profits) (Ad) Free SDMHF Stock Alerts $279.50 0.00 (0.00%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$279.50▼$279.5050-Day Range$240.50▼$299.8652-Week Range$175.12▼$321.11VolumeN/AAverage Volume337 shsMarket CapitalizationN/AP/E Ratio64.85Dividend Yield0.43%Price TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartShort InterestStock AnalysisAnalyst ForecastsChartShort Interest Get Sartorius Stedim Biotech alerts: Email Address Ad WealthPressA lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. Click here to jump in on the next one About Sartorius Stedim Biotech Stock (OTCMKTS:SDMHF)Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.Read More SDMHF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SDMHF Stock News HeadlinesFebruary 28, 2024 | morningstar.comSartorius Stedim Biotech SA ADR SRTOYFebruary 20, 2024 | finance.yahoo.comSartorius Stedim Biotech S.A. (SDMHF)March 29, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…February 7, 2024 | marketwatch.comSartorius Stedim Biotech Shares Fall After Capital IncreaseFebruary 7, 2024 | marketwatch.comSartorius Stedim Biotech Completes $1.3 Bln Capital IncreaseJanuary 26, 2024 | markets.businessinsider.comSartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2023 and provides 2024 guidance as well as new midterm outlookOctober 19, 2023 | finance.yahoo.comSARTORIUS (SARTF) Q3 Earnings Lag EstimatesJuly 21, 2023 | markets.businessinsider.comSartorius Stedim Biotech SA: Half-year results 2023 of Sartorius Stedim BiotechMarch 29, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.July 21, 2023 | markets.businessinsider.comSartorius Stedim Biotech H1 Profit, Orders Down; Backs Weak FY23 OutlookApril 20, 2023 | markets.businessinsider.comSartorius Stedim Biotech Q1 Profit Declines, Sales Revenue Down 18.4% Organically; Confirms OutlookJanuary 26, 2023 | markets.businessinsider.comSartorius Stedim Biotech FY22 Profit Rises, Orders Down; Sees Growth In FY23; Raises FY25 Sales ViewJanuary 26, 2023 | technews.tmcnet.comPreliminary results 2022 of Sartorius Stedim BiotechOctober 19, 2022 | finance.yahoo.comNine-month results 2022 of Sartorius Stedim BiotechJuly 21, 2022 | markets.businessinsider.comSartorius Stedim Biotech H1 Profit Climbs; Confirms FY22 Outlook - Quick FactsApril 21, 2022 | investing.comSartorius Stedim Earnings Miss, Revenue Beats In Q1April 21, 2022 | seekingalpha.comSartorius Stedim Biotech S.A. Non-GAAP EPS of €2.21, revenue of €862.5MFebruary 8, 2022 | seekingalpha.comSartorius Stedim acquires Novasep's chromatography division; boosts sales guidanceJanuary 28, 2022 | seekingalpha.comSartorius Stedim Biotech Non-GAAP EPS of €7.46, revenue of €2.89BNovember 17, 2021 | benzinga.comSingle-use Bioreactors Market worth $8.8 billion by 2026 – Major Players are Sartorius Stedim Biotech (France), Thermo Fisher Scientific (US)November 16, 2021 | finance.yahoo.comLooking for a Growth Stock? 3 Reasons Why SARTORIUS (SARTF) is a Solid ChoiceAugust 23, 2021 | finance.yahoo.comMcMaster, Sartorius Stedim Biotech team up to advance biomanufacturing processes with next-gen techSee More Headlines Receive SDMHF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sartorius Stedim Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medical Instruments & Supplies Sub-IndustryN/A Current SymbolOTCMKTS:SDMHF CUSIPN/A CIKN/A Webwww.sartorius.com Phone(344) 284-5600FaxN/AEmployees10,662Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio64.85 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Rene Faber (Age 49)CEO & DIrector Comp: $590.89kMr. Rainer Lehmann (Age 49)CFO & Member of Executive Board Ms. Petra MullerHead of Investor RelationsMs. Petra Kirchhoff (Age 55)Head of Corporate Communications & IR Olivier GuitardHead of Controlling BPSKey CompetitorsAddLife AB (publ)OTCMKTS:ADDLFAnsellOTCMKTS:ANSLYAnsellOTCMKTS:ANSLFAsahi InteccOTC:AHICFBATM Advanced CommunicationsOTCMKTS:BTAVFView All Competitors SDMHF Stock Analysis - Frequently Asked Questions Should I buy or sell Sartorius Stedim Biotech stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sartorius Stedim Biotech in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SDMHF shares. View SDMHF analyst ratings or view top-rated stocks. How have SDMHF shares performed in 2024? Sartorius Stedim Biotech's stock was trading at $263.75 on January 1st, 2024. Since then, SDMHF stock has increased by 6.0% and is now trading at $279.50. View the best growth stocks for 2024 here. Is Sartorius Stedim Biotech a good dividend stock? Sartorius Stedim Biotech (OTCMKTS:SDMHF) pays an annual dividend of $1.20 per share and currently has a dividend yield of 0.84%. The dividend payout ratio is 27.84%. This payout ratio is at a healthy, sustainable level, below 75%. How do I buy shares of Sartorius Stedim Biotech? Shares of SDMHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SDMHF) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sartorius Stedim Biotech S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.